Mylan’s roots are in the U.S., and our products can likely be found in most American homes. In 2016 alone, our generics saved the nation’s healthcare system approximately $25 billion. As for manufacturing, a majority of the doses we sell in America are manufactured in America.*
*Manufactured from domestic and imported components.
Innovation and science are cornerstones of Mylan’s success for nearly 60 years. They will continue to be the foundation of our future.
One of the most powerful ways to serve patients in need is by speaking out on their behalf.
Mylan understands the importance of going beyond our business boundaries to serve the community at large. Through community engagement and philanthropy, we drive access to high quality medicine and build healthy communities, often aligning our community support to our mission and core business through product donations, financial contributions and employee volunteerism.Through one of our distribution partners, Dispensary of Hope, Mylan has donated approximately 4.5 million doses of medicine to patients in Illinois since 2012.
Epinephrine is the only first-line treatment for anaphylaxis, a potentially life-threatening allergic reaction. Several years ago, we recognized that epinephrine auto-injectors needed to be as accessible as defibrillators are in public spaces. So Mylan advocated for legislation to permit “undesignated” epinephrine auto-injectors in schools – meaning a prescription could be in a school’s name rather than in a child’s name and any individual experiencing an anaphylactic emergency would have access to the epinephrine auto-injectors. Today, 48 states have adopted such laws, and Mylan has donated nearly 1 million epinephrine auto-injectors to more than 73,000 schools around the country through the school access program.